08:00 , Nov 12, 2015 |  BC Innovations  |  Translation in Brief

First world problems

As the microbiome sheds its status as fringe science and moves to the mainstream, leading researchers are grappling with how to solve problems and create common standards that will set the field on the right...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Harvard Scientific Corp, Biosphere Technologies Inc deal

HVSF acquired exclusive rights to Prostaglandin E-1 Lyophilized Liposomes to treat psoriasis from its parent company, Biosphere Technologies. (HVSF to start clinical trials, B11). Harvard Scientific Corp . (HVSF), Reno, Nev.   Biosphere Technologies Inc...
07:00 , Sep 20, 2010 |  BC Week In Review  |  Company News

BioSphere, Merit Medical Systems deal

Merit closed its acquisition of BioSphere for $96 million in cash (see BioCentury, May 24). BioSphere Medical Inc. , Rockland, Mass.   Merit Medical Systems Inc. (NASDAQ:MMSI), South Jordan, Utah   Business: Genitourinary, Cancer, Cardiovascular...
07:00 , May 24, 2010 |  BC Week In Review  |  Company News

BioSphere, Merit Medical Systems deal

Device company Merit will acquire BioSphere for $4.38 per share, or about $96 million in cash. The price is a 46% premium to BioSphere's close of $3 on May 13, before the deal was announced....
08:00 , Feb 9, 2009 |  BC Week In Review  |  Company News

Molecular Insight management update

Molecular Insight Pharmaceuticals Inc. (NASDAQ:MIPI), Cambridge, Mass.   Business: Cancer, Cardiovascular, Diagnostic   Transitioned: John Babich to CEO from interim chairman and CEO while remaining president and CSO; Anthony Martin, a director, becomes non-executive chairman...
08:00 , Dec 24, 2007 |  BC Week In Review  |  Clinical News

HepaSphere Microspheres regulatory update

BSMD received CE Mark approval in the EU for use of its HepaSphere Microspheres to deliver doxorubicin in transarterial chemoembolization procedures to treat hepatocellular carcinoma. As a condition of the approval, the company has agreed...
08:00 , Mar 3, 2003 |  BC Week In Review  |  Clinical News

SkyePharma preclinical data

SKP published in Drug Delivery Systems & Sciences that its Biosphere technology delivered human growth hormone over an extended period of time in animals. The company said Biosphere preserved protein structure and function. SkyePharma plc...
07:00 , May 20, 2002 |  BC Week In Review  |  Company News

Bioglan, Shire Pharmaceuticals Group plc, SkyePharma deal

SKP granted SHP European marketing rights to its Solaraze diclofenac, a non-steroidal anti-inflammatory drug to treat actinic keratosis, for £12.9 million ($18.9 million). SKP is eligible for an additional £2.1 million payment related to launches...
07:00 , May 13, 2002 |  BC Extra  |  Company News

Shire, SKP Solaraze deal

SkyePharma (LSE:SKP; SKYE) granted Shire (LSE:SHP; SHPGY) European marketing rights to its Solaraze diclofenac, a non-steroidal anti-inflammatory drug to treat actinic keratosis, for L12.9 million ($18.9 million). SKP is eligible for an additional L2.1 million...
07:00 , Jul 10, 2001 |  BC Extra  |  Financial News

Sepracor raises $22 million

SEPR, which is developing therapeutics for respiratory, urological and CNS disorders, raised $22 million through the sale of 2 million shares of BioSphere Medical (BSMD) that were owned by SEPR. SEPR received the stake in...